ClinicalTrials.gg
Status unknownNCT01366391Updated Jun 6, 2011

Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome

A Phase 4 interventional study of Metformin in Polycystic Ovary Syndrome, sponsored by Biocinese. Status unknown at 1 site in Brazil. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2011-06-06.

Sponsored by Biocinese · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2011), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 114 studies testing metformin in Polycystic Ovary Syndrome — 9 open to participants now, 11 under way, 3 of them phase 3. Metformin · Polycystic Ovary Syndrome.

Planned enrollment
99th of 113
24 · median 75
Started
2011
with 6 others
Phase 4
33 of 114
1 open now
Registered
34th of 114
by date

Among the 114 studies testing metformin in Polycystic Ovary Syndrome, this one is the 99th largest by planned enrollment of the 113 interventional ones that give a count, is one of 7 that started in 2011, is one of 33 in phase 4, and was the 34th registered.

Polycystic Ovary Syndrome

958 studies on the registry are indexed under Polycystic Ovary Syndrome; 175 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

9 of the 114 studies testing metformin in Polycystic Ovary Syndrome are open now, in 11 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies testing metformin in Polycystic Ovary Syndrome, or all of them as a file.
02

Study summary

Metformin is one of the most commonly prescribed drugs worldwide for the treatment of Type 2 Diabetes. It has been currently used for the treatment of: polycystic ovary syndrome, gestational diabetes, metabolic syndrome and obesity. In patients with polycystic ovary syndrome (PCOS) the adverse side effects are a frequent cause for treatment discontinuation. In every day medical practice lower doses of Metformin are administered searching for the continuation of the treatment.

However, there is no clinical study to support this assertion. The objective of this study is to monitor and correlate the therapeutic effect of Metformin on patients with PCOS taking daily doses of 1500mg and 1000mg.

Read the detailed description

Patients with PCOS diagnosis and that are able to attempt the inclusion criteria are divided in two groups: administration of metformin 500 mg tablet three times/day as well 1500 mg/day (group A)and administration of metformin 500 mg tablet twice/day or 1000 mg/day (group B). Blood samples were collected to the pharmacokinetic evaluation from first day of administration until 3 months after beginning of treatment. The patients are monitored during 3 months and all side effects are register. The efficacy of both treatment are analyzed by biochemical and physical evaluation.

03

Conditions studied

  • Polycystic Ovary Syndrome

Keywords

  • polycystic ovary syndrome
  • metformin
  • pharmacokinetic
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 18 and 40 years old, with no use of drugs or insulin sensitizing agents for more than 3 months.
  • PCOS diagnosis.
  • Insulin resistance Index by the Homeostatic model Assessment Formula higher than 2.5.

Exclusion criteria

Exclusion Criteria:

  • Another diseases with androgen excess;
  • Patients with history of serious adverse reaction or hypersensibility to any medicine;
  • History or presence of renal, hepatic or gastrointestinal disorders.
  • Continuous use of any pharmaco, inclusively metformin
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Other
    Metformin

    study parallel with one arm only.

    Drug: Metformin

Interventions

  • Metformin 500 mg tablet (1000 or 1500 mg/day)

    Also known as: Glifage 500 mg

06

What researchers measure

Primary outcomes

  1. Plasma concentration of metformin

    Blood samples are collected from each patient and the plasma concentration is analysed.

    Time frame: First day after administration until 3 months after begining of treatment

Secondary outcomes

  1. Number of adverse events

    All adverse events are registered during the treatment

    Time frame: observation during 3 months of treatment

07

Study locations

1 of 1 sites recruiting
  • Biocinese
    Toledo, Parana 85903-590, Brazil
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Aug 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2011
First posted
Jun 6, 2011
Start
Jan 2011
Primary completionEst.
Aug 2011
CompletionEst.
Oct 2011
Last update
Jun 6, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01366391
Lead sponsor
Biocinese
First posted
Jun 6, 2011
Start date
Jan 2011
Primary completion
Aug 2011 (estimated)
Completion
Oct 2011 (estimated)
Last update
Jun 6, 2011

Study contacts

Naura Angonese, Dr
Contact
naura.tonin@hotmail.com
+55 45 2103 1900
Josélia Manfio, Dr
Contact
manfiojoselia@bol.com.br
+55 45 21031907
Naura Angonese, Dr
principal investigator · Biocinese

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion